Screener
Fulgent Genetics, Inc. FLGT Therapeutic Development — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
FAQ
- What is Fulgent Genetics, Inc.'s therapeutic development — goodwill?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — goodwill of $22.35M in Q1 2026.
- How has Fulgent Genetics, Inc.'s therapeutic development — goodwill changed year-over-year?
- Fulgent Genetics, Inc.'s therapeutic development — goodwill increased by 1.1% year-over-year, from $22.1M to $22.35M.
- What does therapeutic development — goodwill mean?
- Reflects the excess purchase price paid for acquisitions within the therapeutic development segment over the fair value of identifiable net assets. It serves as an indicator of the premium paid for expected future synergies and the strategic value of acquired research pipelines.
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude